SVB Wealth’s Charles River Laboratories CRL Stock Holding History

SVB Wealth’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-606	Closed	-$250K	–	846
2021 Q3	$250K	Buy	+606	New	+$252K	﹤0.01%	843

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth's CRL Position: Q4 2021 in Review

SVB Wealth sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 606 shares — an estimated $250K sold.

SVB Wealth first reported a position in CRL in Q3 2021 and held it in 1 quarter. The position peaked at $250K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

SVB Wealth reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
SVB Wealth sold 606 Charles River Laboratories shares in Q4 2021, an estimated $250K.
SVB Wealth first reported a position in Charles River Laboratories in Q3 2021 and held it in 1 quarter.
SVB Wealth's Charles River Laboratories position peaked at $250K in Q3 2021.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on SVB Wealth's 13F filing for Q4 2021, filed 15 Feb 2022.